OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo

Despite its relative rarity, pancreatic ductal adenocarcinoma (PDAC) accounts for a large percentage of cancer deaths. In this study, we investigated the in vitro efficacy of OSI-027, a selective inhibitor of mammalian target of rapamycin complex 1 (mTORC1) and mTORC2, to treat PDAC cell lines alone...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhi, Xiao, Chen, Wei, Xue, Fei, Liang, Chao, Chen, Bryan Wei, Zhou, Yue, Wen, Liang, Hu, Liqiang, Shen, Jian, Bai, Xueli, Liang, Tingbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694897/
https://www.ncbi.nlm.nih.gov/pubmed/26213847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694897/
https://www.ncbi.nlm.nih.gov/pubmed/26213847

Ejemplares similares